CAL
FHTX icon

Capital Analysts LLC’s Foghorn Therapeutics FHTX Stock Holding History

Capital Analysts LLC’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-547
Closed -$3K – 1326
2024
Q2 		$3K Hold
547
– – ﹤0.01% 1080
2024
Q1 		$4K Hold
547
– – ﹤0.01% 996
2023
Q4 		$4K Hold
547
– – ﹤0.01% 974
2023
Q3 		$3K Sell
547
-58
-10% -$447 ﹤0.01% 1017
2023
Q2 		$5K Hold
605
– – ﹤0.01% 883
2023
Q1 		$4K Hold
605
– – ﹤0.01% 878
2022
Q4 		$4K Hold
605
– – ﹤0.01% 928
2022
Q3 		$5K Hold
605
– – ﹤0.01% 883
2022
Q2 		$8K Hold
605
– – ﹤0.01% 824
2022
Q1 		$9K Hold
605
– – ﹤0.01% 760
2021
Q4 		$14K Hold
605
– – ﹤0.01% 766
2021
Q3 		$8K Hold
605
– – ﹤0.01% 815
2021
Q2 		$6K Hold
605
– – ﹤0.01% 798
2021
Q1 		$8K Buy
+605
New +$9.91K ﹤0.01% 819

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Analysts LLC's FHTX Position: Q3 2024 in Review

Capital Analysts LLC sold out of Foghorn Therapeutics (FHTX) in Q3 2024, closing a stake of 547 shares — an estimated $3K sold.

Capital Analysts LLC first reported a position in FHTX in Q1 2021 and held it in 14 quarters. The position peaked at $14K in Q4 2021. 79 funds tracked by Wall St. Rank hold FHTX as of Q3 2024.

  • Capital Analysts LLC reported no remaining Foghorn Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capital Analysts LLC sold 547 Foghorn Therapeutics shares in Q3 2024, an estimated $3K.
  • Capital Analysts LLC first reported a position in Foghorn Therapeutics in Q1 2021 and held it in 14 quarters.
  • Capital Analysts LLC's Foghorn Therapeutics position peaked at $14K in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2024.

Based on Capital Analysts LLC's 13F filing for Q3 2024, filed 13 Nov 2024.